Tags

Type your tag names separated by a space and hit enter

Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
Am J Cardiol. 2007 Jun 01; 99(11):1538-43.AJ

Abstract

In a large randomized trial of statin therapy in patients of South-Asian origin with hypercholesterolemia, 740 patients in the United States and Canada received 6 weeks of treatment with rosuvastatin 10 or 20 mg or atorvastatin 10 or 20 mg. A total of 485 patients (66%) were categorized as being at high risk of coronary heart disease and had a National Cholesterol Education Program Adult Treatment Panel III treatment goal of low-density lipoprotein (LDL) cholesterol <100 mg/dl (<2.6 mmol/L). LDL cholesterol decreased by 45% with rosuvastatin 10 mg versus 40% with atorvastatin 10 mg (p = 0.0023) and by 50% with rosuvastatin 20 mg versus 47% with atorvastatin 20 mg (p = NS). National Cholesterol Education Program Adult Treatment Panel III LDL cholesterol goal achievement rates in high-risk patients (all patients) were 76% (79%) and 88% (89%) with rosuvastatin 10 and 20 mg, respectively, compared with 70% (76%) and 81% (85%) with atorvastatin 10 and 20 mg, respectively. Rosuvastatin and atorvastatin were well tolerated. There were no clinically relevant differences between statins in adverse events or incidence of creatine kinase >10 times the upper limit of normal, alanine aminotransferase >3 times the upper limit of normal on 2 consecutive occasions, or proteinuria or hematuria over the relatively short duration of treatment. In conclusion, statin therapy was well tolerated and effective in decreasing LDL cholesterol in patients of South-Asian origin, with the 10- and 20-mg doses of rosuvastatin and atorvastatin allowing most patients to reach recommended LDL cholesterol goals.

Authors+Show Affiliations

Veterans Affairs Central California Health Care System, University of California-San Francisco, Fresno, California, USA. deed@fresno.ucsf.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17531577

Citation

Deedwania, Prakash C., et al. "Comparison of Rosuvastatin Versus Atorvastatin in South-Asian Patients at Risk of Coronary Heart Disease (from the IRIS Trial)." The American Journal of Cardiology, vol. 99, no. 11, 2007, pp. 1538-43.
Deedwania PC, Gupta M, Stein M, et al. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol. 2007;99(11):1538-43.
Deedwania, P. C., Gupta, M., Stein, M., Ycas, J., & Gold, A. (2007). Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). The American Journal of Cardiology, 99(11), 1538-43.
Deedwania PC, et al. Comparison of Rosuvastatin Versus Atorvastatin in South-Asian Patients at Risk of Coronary Heart Disease (from the IRIS Trial). Am J Cardiol. 2007 Jun 1;99(11):1538-43. PubMed PMID: 17531577.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). AU - Deedwania,Prakash C, AU - Gupta,Milan, AU - Stein,Michael, AU - Ycas,Joseph, AU - Gold,Alex, AU - ,, Y1 - 2007/04/16/ PY - 2006/10/04/received PY - 2006/12/20/revised PY - 2007/01/10/accepted PY - 2007/5/29/pubmed PY - 2007/8/3/medline PY - 2007/5/29/entrez SP - 1538 EP - 43 JF - The American journal of cardiology JO - Am J Cardiol VL - 99 IS - 11 N2 - In a large randomized trial of statin therapy in patients of South-Asian origin with hypercholesterolemia, 740 patients in the United States and Canada received 6 weeks of treatment with rosuvastatin 10 or 20 mg or atorvastatin 10 or 20 mg. A total of 485 patients (66%) were categorized as being at high risk of coronary heart disease and had a National Cholesterol Education Program Adult Treatment Panel III treatment goal of low-density lipoprotein (LDL) cholesterol <100 mg/dl (<2.6 mmol/L). LDL cholesterol decreased by 45% with rosuvastatin 10 mg versus 40% with atorvastatin 10 mg (p = 0.0023) and by 50% with rosuvastatin 20 mg versus 47% with atorvastatin 20 mg (p = NS). National Cholesterol Education Program Adult Treatment Panel III LDL cholesterol goal achievement rates in high-risk patients (all patients) were 76% (79%) and 88% (89%) with rosuvastatin 10 and 20 mg, respectively, compared with 70% (76%) and 81% (85%) with atorvastatin 10 and 20 mg, respectively. Rosuvastatin and atorvastatin were well tolerated. There were no clinically relevant differences between statins in adverse events or incidence of creatine kinase >10 times the upper limit of normal, alanine aminotransferase >3 times the upper limit of normal on 2 consecutive occasions, or proteinuria or hematuria over the relatively short duration of treatment. In conclusion, statin therapy was well tolerated and effective in decreasing LDL cholesterol in patients of South-Asian origin, with the 10- and 20-mg doses of rosuvastatin and atorvastatin allowing most patients to reach recommended LDL cholesterol goals. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/17531577/Comparison_of_rosuvastatin_versus_atorvastatin_in_South_Asian_patients_at_risk_of_coronary_heart_disease__from_the_IRIS_Trial__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(07)00364-5 DB - PRIME DP - Unbound Medicine ER -